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The microbiota is now recognised as a key influence on the host
immune response in the central nervous system (CNS). As such,
there has been some progress towards therapies that modulate
the microbiota with the aim of limiting immune-mediated demyeli-
nation, as occurs in multiple sclerosis. However, remyelination
– the regeneration of myelin sheaths – also depends upon an
immune response, and the effects that such interventions might
have on remyelination have not yet been explored. Here, we show
that the inflammatory response during CNS remyelination in mice
is modulated by antibiotic or probiotic treatment, as well as in
germ-free mice. We also explore the effect of these changes on
oligodendrocyte progenitor cell differentiation, which is inhibited
by antibiotics but unaffected by our other interventions. These
results reveal that high combined doses of oral antibiotics impair
oligodendrocyte progenitor cell responses during remyelination
and further our understanding of how mammalian regeneration
relates to the microbiota.
microbiota | remyelination | microglia | macrophage | oligodendro-
cyte progenitor cell
Introduction
Our knowledge of the microbiota and its relationship with host
immunity, metabolism and neurobiology has significantly ex-
panded in recent years (1). However, the role of the microbiota
in mammalian regeneration remains relatively unexplored. As
endogenous tissue regeneration is facilitated by a local immune
response (2), it is feasible that intestinal microbes, which modu-
late the host immune system (3, 4), could help shape the outcome
of regeneration in a clinical setting. The gut microbial community
can be easily modified using oral antibiotics or probiotics, thus
addressing this question is of great clinical relevance.
Here, we investigate how the intestinal microbiota influences
remyelination, the most effective form of regeneration observed
in the mammalian central nervous system (CNS) and a promising
therapeutic strategy for multiple sclerosis (MS) and other myelin
diseases (5). Successful remyelination can bring functional recov-
ery (6, 7) and protect axons from degeneration (8). This success
depends on an inflammatory response by microglia and infiltrat-
ing macrophages (9) that progresses and resolves appropriately
(10, 11). Due to its distance from any epithelial interface with
environmental microbes, CNS remyelination is an ideal model to
explore systemic influences of the microbiota on regeneration.
The rationale for our studies is based on the close relation-
ship between remyelination and the innate immune response,
and in turn between the immune system and the microbiota. To
create an environment that permits remyelination, endogenous
microglia and infiltrating macrophages must clear myelin debris
remaining from the disintegrated sheath (12), and also secrete
pro-regenerative factors (10, 11, 13). These roles hinge upon a
coordinated immune response to demyelination, failure of which
can impair remyelination, as occurs in older animals (14, 15).
Meanwhile, there is now a substantial body of evidence linking
the microbiota to CNS inflammation across various contexts. For
example, germ-free or antibiotics-treated mice have transcrip-
tionally immature microglia, which have an impaired response to
lipopolysaccharide (LPS) or viral stimulation (3), whilst antibiotic
depletion of the microbiota reduces monocyte entry into the
brain (4). The immune system is therefore a strong candidate for
conveying an influence from the microbiota to regeneration in
distant tissues such as the CNS.
There is a growing appreciation of the relationship between
the microbiota and MS. Patients with MS have a distinct micro-
biome compared to healthy controls (16, 17), and this may have
a role in disease pathogenesis, given that faecal transplant from
patients with MS can provoke immune-mediated demyelination
in predisposed germ-free mice (18). Much focus has centred upon
antibiotic or probiotic interventions that aim to limit demyeli-
nation in MS and animal models (19–21). However, the effects
Significance
People with multiple sclerosis have a distinct microbiota to
healthy controls, and there is growing interest in how these
differences might contribute to the onset and progression of
CNS autoimmunity. However, the impact that the microbiota
may also have on the endogenous regeneration of myelin –
remyelination – has not yet been explored. Here we show that
inflammatory responses during remyelination depend upon
the microbiota, being modulated by antibiotics, probiotics or
in germ-free mice. In contrast, these interventions had minimal
impact on the activity of oligodendrocyte progenitor cells,
with only supra-therapeutic doses of antibiotics having an
inhibitory effect. Our results suggest that endogenous CNS
remyelination is largely resilient to interventions that modify
the microbiota.











































































































































Fig. 1. Antibiotics treatment to deplete the microbiota alters the inflammatory response following lysolecithin-mediated demyelination.(A) Mice were
administered ABX in their drinking water for 2 months, after which one group received a faecal microbial transplant (FMT) whilst another group were
continued on ABX. Mice were sacrificed at 7 and 14 days following lysolecithin injection into the ventral white matter of the spinal cord.(B) RT-PCR of
faecal DNA showing depletion of the microbiota by ABX and return to normal levels with FMT.(C-D) Representative images (C) and density (D) of CD68hi
activated microglia/macrophages within the lesion boundary (yellow line).(E-G) Representative images (E) and density of Tmem119+CD68hi microglia-derived
(F) and Tmem119-CD68hi monocyte-derived (G) CD68hi cells within lesions.(H-J) Representative images (H) and density of P2ry12hiClec7a- homeostatic (I) and
P2ry12loClec7a+ (J) degeneration-associated microglia/macrophages within lesions.Scale bars: (C) = 250μm, (E, H) = 200μm [inset: 25μm]. Insets (E, H) are a 3x
magnification of the boxed regions. Error bars show mean ± SEM; *p<0.05, **p<0.01, ***p<0.001; (B) Kruskal-Wallis with Dunn’s post hoc test; (D, F-G, I-J)
one-way ANOVA with Tukey HSD post hoc test, n=4-6 mice.
that such treatments might have on remyelination remain to be
elucidated.
Here we use a variety of interventions to alter the murine
microbiota, before quantifying inflammation and oligodendro-
cyte progenitor cell (OPC) activity in response to toxin-induced
demyelination. Across antibiotics-treated, probiotic-treated and
germ-free mice, altering the microbiota was found to modulate
the inflammatory response following demyelination. However,
no clear relationship emerged between the microbiota, the OPC
response to demyelination and subsequent remyelination.
Results
Combined antibiotics treatment to deplete the microbiota alters
inflammation following toxin-induced demyelination
To explore whether extensive microbial depletion would af-
fect remyelination, C57BL/6 mice were administered broad-
spectrum antibiotics (ABX) in their drinking water for 8
weeks (Fig. 1A). This combination of ampicillin/sulbactam,
ciprofloxacin, vancomycin, metronidazole and imipenem has pre-
viously been shown to cause depletion of the microbiota (4),
which we confirmed by quantitative RT-PCR of faecal DNA
(Fig. 1B). Demyelination was then induced by focal injection of
lysolecithin into the ventral white matter of the spinal cord.
To investigate baseline differences in microglia following
ABX treatment, areas of unlesioned white matter were stained
with an antibody to Iba1. Microglial morphology, which correlates
with activity within a given tissue (3, 22), was then analysed (Fig.
S1A). Whilst a principal component analysis based on a number
of morphological features showed clear separation between mi-
croglia from grey and white matter, there were no differences
detected in microglia of unlesioned white matter following ABX
treatment (Fig. S1B, C). This approach gave a useful indication
of baseline microglial function, though we cannot exclude subtle
differences that may have been resolved with more sensitive
tools such as 3-dimensional morphometric analysis or RNA-
sequencing (3).
The inflammatory response within lesions was examined at
7 and 14 days post lesion (dpl) by staining for CD68. Whilst
CD68 is constitutively expressed at low levels in homeostatic











































































































































Fig. 2. Fewer new oligodendrocytes are generated in the lesions of ABX-treated mice.(A-B) Representative images (A) and area (B) of dMBP+ myelin debris
within lesions.(C-E) Representative images (C) and densities of Olig2+CC1- OPCs (D) and Olig2+CC1+ oligodendrocytes (E) within lesions. (F-G) Representative
images (F) and quantification (G) of NF+ axons and MBP+ myelin sheaths within lesions. Scale bars: (A) = 250μm, (C) = 100μm, (F) = 100μm [inset: 20μm]. Insets
(F) are a 10x magnification of the boxed regions. Error bars show mean ± SEM; *p<0.05; one-way ANOVA with Tukey HSD post hoc test, n=4-6 mice.
Fig. 3. Antibiotics treatment does not affect microglia phagocytosis or OPC responses in vitro.(A) Primary microglia were isolated from 3-month old mice
using magnetic-activated cell sorting (MACS) for CD11b, cultured for 48 hours in the presence of antibiotics, then exposed to myelin debris for 4 hours.(B)
Microglia were stained with an antibody to MBP to visualise myelin uptake.(C) Myelin uptake following exposure to combined antibiotics at their estimated
CNS concentration (++) or a 10% dose (+) was comparable to control levels.(D) Primary OPCs were isolated from P6-8 mice using MACS for A2B5. After 4
days, antibiotics were applied, and growth factors were withdrawn to allow differentiation for 6 further days.(E-H) Cells were stained with an antibody to
Olig2 in combination with labelling incorporated EdU to visualise proliferation (E) or CNPase to visualise differentiation (G). The antibiotic treatments had
no significant effect on OPC proliferation (F) or differentiation (H).Scale bars: (B, E, G) = 100μm. Error bars show mean ± SEM; paired-samples t-test with
Holm-Bonferroni correction, n=4-5 separate experiments.
– a population comprising activated microglia as well as infil-
trating macrophages. At 7dpl, the density of CD68hi cells was
similar between ABX-treated mice and specific pathogen-free
(SPF) controls (Fig. 1C, D), with no difference in lesion size
(Fig. S1D). However, at 14dpl, the total density of CD68hi ac-
tivated microglia/macrophages was increased in lesions of mice
that had received ABX treatment (Fig. 1C, D). To determine
the reversibility of this effect, ABX-treated mice received a fae-
cal microbial transplant (FMT) from SPF mice by oral gavage
to reconstitute their microbiota. With FMT treatment, CD68hi
cell density remained higher than in SPF controls (Fig. 1D).
We then asked whether the differences were driven primarily
by microglia or infiltrating monocytes, by co-staining for CD68
with Tmem119, a stable marker for microglia (24). We observed
that both CD68hiTmem119+ microglia and CD68hiTmem119-
monocyte-derived macrophages were increased in number with
ABX-treatment (Fig. 1E-G).
Subpopulations of microglia/macrophages are known to have
distinct effects in remyelination (11). We used antibodies to
P2ry12 and Clec7a to identify homeostatic (P2ry12hiClec7a-) and
degeneration-associated (P2ry12loClec7a+) phenotypes (25, 26).
At 14dpl, as well as a higher total number of CD68hi cells,
lesions of ABX-treated mice had fewer P2ry12hiClec7a- home-
ostatic microglia (Fig. 1H, I) and more of the P2ry12loClec7a+
degeneration-associated phenotype (Fig. 1H, J) than in SPF
controls. We also identified a population within all lesions that
expressed both high levels of P2ry12 and Clec7a (Fig. S1O).
Staining for a panel of other microglia/macrophage markers with
recognised roles in remyelination (Fig. S1E-L) revealed further
differences between ABX-treated mice and controls. At the 7dpl
timepoint, ABX-treated mice had fewer CD68hi cells expressing
MHC class II (MHC II, Fig. S1E, F) or arginase-1 (Arg1, Fig.
S1G, H), with variable reversal following FMT.
Taken together, these results indicate that broad-spectrum
antibiotic treatment results in dysregulated CNS inflammation
following demyelination. Specifically, we observed an increase
in total CD68hi cells from 7 to 14dpl in ABX-treated groups,











































































































































Fig. 4. Germ-free mice have an altered inflammatory response following cuprizone-mediated demyelination.(A) GF mice and SPF controls were fed a diet
containing 0.2% cuprizone for 5weeks from 8weeks of age.Micewere sacrificed at the end of cuprizone administration, or after 3weeks return to normal diet.
A third group consisted of GF mice that were co-housed with SPF mice from 4 weeks of age, becoming colonised with a microbiota after weaning.(B) PCR for a
universal prokaryotic 16S sequence in faecal DNA, demonstrating absence of this amplicon in GF mice and its presence in the ex-GF group.(C-D) Representative
images (C) and density (D) of CD68hi activated microglia/macrophages within the corpus callosum (yellow line) in cuprizone-naïve mice, following 5 weeks
cuprizone exposure (5w) and following a further 3 weeks of normal diet (5+3w).(E-G) Representative images (E) and density of P2ry12hiClec7a- homeostatic
(F) and P2ry12loClec7a+ (G) degeneration-associated microglia/macrophages within the corpus callosum.Scale bars: (C, E) = 100μm. Error bars show mean ±
SEM; *p<0.05, **p<0.01, ***p<0.001; one-way ANOVA with Tukey HSD post hoc test, n=4-5 mice.
and Arg1 expression by microglia/macrophages in the ABX-
treated groups were reduced at 7dpl, and at the later timepoint
there was a preponderance of the degeneration-associated mi-
croglia/macrophages with reduced numbers of P2ry12hiClec7a-
homeostatic microglia. Thus, our microbial depletion model was
dominated by a delayed but aggressive pro-inflammatory innate
immune response.
Combined antibiotics treatment impairs myelin debris clear-
ance and OPC differentiation
Central to CNS remyelination is the generation of new oligo-
dendrocytes to restore the myelin sheath. These derive from en-
dogenous OPCs, which migrate to lesions­­­, proliferate and sub-
sequently differentiate into oligodendrocytes (5, 27). Defective
differentiation from OPC to oligodendrocyte is commonly the
bottleneck at which remyelination fails in human lesions and ani-
mal models (28–30). Microglia and infiltrating macrophages pro-
mote remyelination through the clearance of myelin debris, which
blocks OPC differentiation in culture (31) and impairs remyelina-
tion in demyelinated lesions (12). We investigated whether the
dysregulated inflammatory response following ABX treatment
would be associated with reduced myelin debris clearance.
Lesions were stained with an antibody for a degraded epi-
tope of myelin basic protein (dMBP), which becomes exposed
in myelin debris (32) (Fig. 2A, B). At 7dpl, antibiotics did not
affect the quantity of myelin debris in the lesion area. By 14dpl
there had been an expected reduction in myelin debris in the SPF
controls: however, this was less pronounced amongst the ABX-
treated group, with more debris persisting at the later timepoint.
The effect was reversed in the FMT group, which had a similar
dMBP+ area to controls.
We next explored how the OPC response would be affected











































































































































Fig. 5. Germ-free mice have reduced oligodendrocyte loss following cuprizone administration, but no difference in OPC differentiation.(A-C) Representative
images (A) and density of Olig2+CC1- OPCs (B) and Olig2+CC1+ mature oligodendrocytes (C) within the corpus callosum in cuprizone-naïve mice, following
5 weeks cuprizone exposure (5w) and following a further 3 weeks of normal diet (5+3w).(D-E) Representative images (D) and density (E) of Olig2+Ki67+
proliferating OPCs within the corpus callosum.(F-G) Representative electron microscopy images (F) and quantification (G) of myelinated axons within the
corpus callosum 3 weeks after cuprizone cessation.Scale bars: (A) = 200μm [inset: 25μm], (D) = 200μm, (F) = 2μm. Insets (A) are a 2.5x magnification of the
boxed regions. Arrow heads (D) show representative double-positive cells. Error bars show mean ± SEM; one-way ANOVA, n=3-5 mice.
label cells of the oligodendrocyte lineage and CC1 to distinguish
differentiated oligodendrocytes (CC1+) from OPCs (CC1-). ABX
did not affect the total number of OPCs present (Fig. 2C, D),
nor the number of proliferating OPCs identified by Ki67 staining
(Fig. S2A, B). However, there were fewer differentiated oligoden-
drocytes in the lesions of ABX-treated mice at 14dpl, suggesting
a defect in OPC differentiation (Fig. 2C, E). This was not re-
stored by FMT in the ABX-treated group. Finally, we quantified
myelinated axons at 14dpl by counting neurofilament+ axons
surrounded by a ring of MBP+ myelin. There were no significant
differences between the groups (p=0.10, Fig. 2F, G).
In summary, following demyelination in ABX-treated mice,
the altered inflammatory response is associated with impaired
myelin debris clearance and impaired OPC differentiation. The
effects of ABX treatment on remyelinating lesions could feasibly
be caused by either ABX-mediated depletion of the microbiota,
other off-target effects of this oral ABX regime, or a combination
of these mechanisms. Two approaches were taken to explore
these possibilities: 1) testing for off-target effects of ABX on
relevant CNS cells in culture and 2) investigating remyelination in
germ-free (GF) mice, which were reared in a sterile environment
and thus were constitutionally devoid of microbes without ABX
exposure.
Combined antibiotics treatment does not affect microglial
phagocytosis or OPC differentiation in vitro
Some antibiotics are able to penetrate and act directly
within the CNS. One example is the broad-spectrum tetracycline,
minocycline, which can directly inhibit microglia and influence re-
myelination (33–35). Four of the antibiotics we administered were
considered to have sufficient bioavailability to reach the CNS in
significant concentrations: ampicillin, ciprofloxacin, metronida-
zole and the β-lactamase inhibitor sulbactam. Available pharma-
cokinetic data were used to estimate the concentrations these
drugs would reach in the murine CNS (Fig. S3A), which were then
applied to adult primary murine microglial cultures for 48 hours
(Fig. 3A). Following ABX treatment, microglia were exposed to
myelin debris and phagocytic uptake was quantified after 4 hours.
None of the ABX individually (Fig. S3C, D), nor in combination
(Fig. 3B, C), directly inhibited myelin phagocytosis by microglia.
To confirm that we were not overlooking any dynamic changes by











































































































































Fig. 6. Probiotic VSL#3 enhances the onset of inflammation following demyelination.(A) 13-month old mice were administered 1.35 x 109 colony-forming
units (CFU) VSL#3 daily for 1 month by oral gavage. Mice were sacrificed at 5 and 14 days following lysolecithin injection into the ventral white matter of the
spinal cord.(B) Constituent strains of VSL#3.(C-D) Representative images (C) and density (D) of CD68hi activated microglia/macrophages within lesions.(E-G)
Representative images (E) and density of Tmem119+CD68hi microglia-derived (F) and Tmem119-CD68hi monocyte-derived (G) CD68hi cells within lesions.(H-
J) Representative images (H) and density of P2ry12hiClec7a- homeostatic (I) of P2ry12loClec7a+ (J) degeneration-associated microglia/macrophages within
lesions.Scale bars: (C) = 250μm, (E, H) = 200μm [inset: 25μm]. Insets (E, H) are a 3x magnification of the boxed regions. Error bars show mean ± SEM; *p<0.05;
Student’s t-test, n=3-5 mice.
Fig. 7. VSL#3 probiotic does not enhance remyelination in aged mice. (A-B) Representative images (A) and area (B) of dMBP+ myelin debris within lesions.
(C-E) Representative images (C) and density of Sox10+CC1- OPCs and (D) and Sox10+CC1+ mature oligodendrocytes (E) within lesions. (F) Representative images
of toluidine blue-stained resin sections demonstrating persistent demyelination, typical of aged mice (CON rank: 4/10, PRO rank: 3/10). Images are shown in
grayscale. (G) Remyelination ranks assigned by a blinded assessor, with horizontal lines showing the median for each group. Scale bars: (A, C) = 250μm, (F) =
100μm [inset: 10μm]. Insets are a 4x magnification of the boxed regions. Error bars show mean ± SEM; (B, D, E) Student’s t-test, n=3-5 mice; (G) Mann–Whitney











































































































































phagocytosis in the presence of the combination treatment and
similarly found no difference to controls conditions (Fig. S3B).
It is also possible that ABX can act directly on OPCs to inhibit
differentiation in lesions of mice receiving oral ABX. To test this,
primary cultures of murine OPCs were treated with ABX and the
effects on differentiation and proliferation were determined by
immunocytochemistry after six days of differentiation conditions
(Fig. 3D). ABX treatment had no effect on OPC proliferation
as measured by EdU incorporation (Fig. 3E-F), nor was there
a difference in expression of the differentiation marker CNPase
(Fig. 3G-H). Similarly, applying each antibiotic alone had no
effect on these parameters (Fig. S3E-H).
Germ-free mice have an altered inflammatory response dur-
ing remyelination
The results from cell culture systems suggest that the deficits
observed in ABX-treated mice are not caused by direct effects of
antibiotics on microglial or OPC functions critical for remyelina-
tion. However, antibiotics may have other indirect effects that are
difficult to capture in vitro. To determine whether the microbiota
can influence remyelination in the absence of ABX exposure,
we investigated how remyelination would proceed in germ-free
(GF) mice. As surgical lesions are impractical under the con-
straints of GF husbandry, we employed the cuprizone model, in
which demyelination is induced by dietary administration of 0.2%
cuprizone over a period of 5 weeks (Fig. 4A). The sterility of the
GF mice was confirmed by faecal PCR for bacterial DNA (Fig.
4B) as well as routine in-house screening of animals and isolators
using aerobic and anaerobic culture methods and microscopy of
faecal smears. An ex-GF group were colonised with a microbiota
after weaning, by co-housing with SPF controls, and this allowed
us to distinguish developmental effects of lacking a microbiota
from those reversible in adulthood. After cuprizone exposure,
all mice were returned to a normal diet for a 3-week period of
remyelination.
GF mice had differences in the inflammatory response that
accompanied demyelination. The total number of CD68hi ac-
tivated microglia and monocyte-derived macrophages was re-
duced in the GF group after the 5-week cuprizone treatment
and remained so 3 weeks after cuprizone was withdrawn (Fig.
4C, D). To investigate this response in more detail, we quanti-
fied homeostatic (P2ry12hiClec7a-) and degeneration-associated
(P2ry12loClec7a+) phenotypes across the three groups (Fig.
4E-G). Degeneration-associated microglia/macrophages accu-
mulated in the corpus callosum following cuprizone exposure, but
this occurred to a much lesser extent in the GF group (Fig. 4G). In
contrast, 3 weeks after cuprizone withdrawal, GF mice had higher
numbers of homeostatic microglia than the other groups (Fig.
4F). Numbers of CD68hi, P2ry12hiClec7a- and P2ry12loClec7a+
cells were all comparable to SPF controls in the ex-GF group,
demonstrating that colonisation of GF mice can restore immune
responsiveness and delineates an ongoing, dynamic role of the
microbiota in the inflammatory response to tissue damage, rather
than a critical window during development.
As with the ABX-treated mice, we sought to distinguish
microglia and monocyte-derived macrophages. However, we ob-
served that Tmem119 was expressed at very low levels within
the corpus callosum following cuprizone exposure (Fig. S4A)
and thus was less useful as a microglia-specific marker in this
context. Instead, we quantified co-expression of Iba1 with P2ry12
(36), which remained detectable (albeit at lower levels in reac-
tive microglia) allowing distinction between Iba1+P2ry12+ mi-
croglia and Iba1+P2ry12- peripheral macrophages (Fig. S4B-
E). Both microglia and monocyte-derived macrophages were
reduced in GF mice after 5 weeks of cuprizone, whilst 3 weeks
later the reduced CD68 expression of GF mice was primarily
associated with reduced numbers of Iba1+P2ry12- peripheral
macrophages (Fig. S4D, E). We also stained for the same panel
of microglia/macrophage markers as tested in the antibiotics ex-
periment. Previously, ABX-treated mice were both found to have
reduced expression of both MHC II and Arg1 during remyeli-
nation (Fig. S1E-H). Here, MHC II was similarly diminished in
the remyelinating corpus callosum of GF mice, with negligible
expression in microglia/macrophages of any of these animals (Fig.
S4F, G). There was no significant reduction in Arg1, despite a
similar trend (Fig. S4H, I), nor was there a difference detected
in iNOS or MR expression in GF mice (Fig. S4J-M).
The deficits in the immune response of ABX-treated mice
were associated with reduced myelin debris clearance after de-
myelination (Fig. 2A, B). A timecourse of cuprizone feeding
in SPF mice showed that extensive dMBP+ myelin debris after
3 weeks of cuprizone diet is subsequently cleared by 5 weeks
(Fig. S4N). We subsequently compared dMBP staining at our
5w timepoint to determine whether myelin debris clearance was
impaired under GF conditions. All groups showed similarly low
levels of dMBP staining at 5w, indicating that any difference in
debris clearance was not persistent beyond 5 weeks (Fig. S4O).
In summary, we observed that the inflammatory response
following demyelination was also altered in GF mice. However,
whilst lesions of ABX-treated mice were characterised by higher
density of degeneration-associated microglia/macrophages, the
opposite was true for cuprizone-treated GF mice, in which home-
ostatic microglia dominated the inflammatory response. The
changes in GF mice suggest that the microbiota can indeed
influence the immune response in the CNS during demyelination
and remyelination; however, in this case there was no associated
change in myelin debris clearance.
Germ-free mice have normal OPC differentiation during
remyelination
Next, the OPC responses during cuprizone-mediated de-
myelination and remyelination were examined in GF mice. Prior
to cuprizone exposure, GF and SPF mice had comparable num-
bers of Olig2+CC1- OPCs (Fig. 5A, B) and Olig2+CC1+ oligo-
dendrocytes (Fig. 5A, C) in the corpus callosum. Following 5
weeks cuprizone treatment, there was an 80% reduction in the
density of Olig2+CC1+ oligodendrocytes in the SPF group (Fig.
5C). In contrast, the loss of oligodendrocytes after 5 weeks of
cuprizone was less extensive amongst the GF group, whilst the
ex-GF group were in line with SPF controls. At this timepoint,
all groups experienced a similar rise in Olig2+CC1- OPCs (Fig.
5B), consistent with the phase of OPC migration and proliferation
known to occur during the first 5 weeks of cuprizone administra-
tion (45). However, when we specifically quantified Olig2+Ki67+
proliferative OPCs at 5 weeks, this was higher in the GF mice than
the other two groups (Fig. 5D, E).
Three weeks after cuprizone withdrawal, a timepoint at which
remyelination should be progressing (37, 38), all three groups
exhibited a fall in OPC counts with a concurrent rise in differen-
tiated oligodendrocytes. Importantly, there were no differences
in OPC or oligodendrocyte numbers between the groups at this
later timepoint (Fig. 5B, C), suggesting that there was no delay in
OPC differentiation during the remyelination of GF mice.
Finally, the degree of remyelination following cuprizone ces-
sation was investigated by transmission electron microscopy (Fig.
5F). The corpus callosum of SPF controls, GF and ex-GF mice all
exhibited comparable densities of myelinated axons 3 weeks after
cuprizone treatment was stopped, indicating that remyelination
had progressed similarly between groups (Fig. 5G). The g-ratios
of these axons were also measured and likewise revealed no
differences (Fig. S5A, B).
In summary, GF mice were partially resistant to the effects
of cuprizone, with less extensive oligodendrocyte loss following
5 weeks of dietary administration. This effect could be related to
their diminished innate immune response during cuprizone treat-











































































































































of the immune system, particularly microglia and neutrophils, in
mediating cuprizone-induced demyelination (39, 40). The late
peak in OPC proliferation observed in the GF group (Fig. 5D,
E), may similarly be in response to a sluggish innate immune
response. However, 3 weeks after cuprizone was stopped, the
absence of any difference in OPC or oligodendrocyte numbers
combined with similar densities of myelinated axons suggest that
remyelination itself is unaffected in GF mice.
Probiotic VSL#3 can augment the innate immune response
during CNS remyelination
Taking the results from the antibiotics and germ-free experi-
ments, together with in vitro studies, an intact microbiota appears
to be necessary for the appropriate inflammatory response during
remyelination. However, the effect that microbial depletion has
on OPC responses, and thus remyelination itself, remains less
certain. We next explored the inverse of this relationship: whether
the microbiota can be manipulated therapeutically to enhance
appropriate inflammatory responses and subsequently remyeli-
nation. For this, we used older mice (aged 14 months) in which
remyelination occurs more slowly with scope for improvement
(14, 41). These mice were administered the probiotic VSL#3 by
daily gavage for 1 month, prior to inducing focal demyelination in
the spinal cord white matter by lysolecithin injection (Fig. 6A).
VSL#3, a freeze-dried formulation of 8 strains of Gram-
positive bacteria (Fig. 6B), was chosen due to its good survival
on transit through the GI tract (42) and several characterised
therapeutic effects in the CNS (4, 43, 44). Additionally, VSL#3
enhanced concentrations of short chains fatty acids (SCFAs) in
the faeces and serum of mice (Fig. S6B, D), consistent with a
previous study (45). The SCFAs acetate, butyrate and propionate
are microbial metabolites that are depleted in GF mice (Fig. S5A,
C) and considered key signalling molecules in how the microbiota
influence CNS inflammation (3, 46).
Following VSL#3 treatment, there was a mild enhancement
in the inflammatory response at 5dpl, with greater density of
CD68hi activated microglia and infiltrating macrophages (Fig. 6C,
D). We again stained for CD68 in combination with Tmem119
to determine which populations of CD68hi cells were affected.
We found that probiotic administration increased numbers of
CD68hiTmem119+ microglia at 5dpl (Fig. 6E, F), though no
difference was detected amongst CD68hiTmem119- monocyte-
derived macrophages (Fig. 6E, G). Staining for P2ry12 and Clec7a
revealed that, despite the increase in total number of CD68hi cells
at 5dpl, the numbers of P2ry12loClec7a+ degeneration-associated
microglia/macrophages were reduced with VSL#3 (Fig. 6H-J),
suggesting a less detrimental inflammatory environment. Both
iNOS and MR were expressed by greater numbers of CD68hi
cells in lesions following probiotic treatment at 5dpl (Fig. S6E-H),
whilst two markers initially reduced by ABX (MHC II and Arg1)
were not significantly enhanced by probiotic treatment (Fig. S6I-
L).
No differences were detected at 14dpl, a timepoint at which
debris should be largely cleared and newly differentiated oligo-
dendrocytes initiate remyelination. Thus, although our probiotic
augmented the initial inflammatory response at 5dpl, the effect
of this on subsequent trajectory of inflammation in the lesion was
more limited.
VSL#3 does not improve the outcome of remyelination
Finally, we assessed whether this inflammatory enhancement
during the early stages would contribute to a better outcome in
remyelination. In contrast to ABX-treated mice, in which the
altered inflammatory response resulted in prolonged presence of
myelin debris, myelin debris was not cleared any faster in the
lesions of probiotic-treated mice (Fig. 7A, B). Consistent with
this, there was no difference in the OPC response, with OPC
number (Fig. 7C, D; Fig. S7A), proliferation (Fig. S7B, C) and
differentiation of new oligodendrocytes at 14dpl (Fig. 7C, E)
unchanged by probiotic treatment. There was a small increase
in the number of oligodendrocytes present at 5dpl (Fig. 7E; Fig.
S7A). As this timepoint is considered too early for significant OPC
differentiation to occur, even in young adults (47) and taking into
account that no difference was observed at 14dpl, the peak time
for OPC differentiation, this likely reflects a reduction in oligo-
dendrocyte death, rather than enhanced OPC differentiation.
To confirm that there was no therapeutic effect of VSL#3
on remyelination, semi-thin resin sections were taken at a later
timepoint (21dpl) and myelin stained with toluidine-blue (Fig.
7F). The completion of remyelination was ranked by two blinded
assessors, neither of whom detected a difference in remyelination
between groups (Fig. 7G).
Thus, administration of the probiotic VSL#3 promoted a
stronger initial inflammatory response in aged mice following
demyelination. However, this did not lead to faster clearance of
myelin debris or OPC differentiation, and overall remyelination
was unchanged compared to control mice.
Discussion
The aim of these experiments was to explore how the micro-
biota can influence remyelination in the mammalian CNS. Across
all three models, the responses of microglia and infiltrating
macrophages were modulated by interventions that altered the
microbiota. Broadly, this amounted to a dysregulated immune
response in ABX-treated mice, and a blunted, more homeostatic-
type response in GF mice. In contrast, VSL#3 probiotic treat-
ment enhanced the onset of inflammation whilst reducing num-
bers of damage-associated microglia/macrophages. As remyelina-
tion depends upon a coordinated immune response (9–11, 48),
such changes might be expected to impact upon the OPC activity
underlying remyelination. Consistent with this hypothesis, ABX-
treated mice had deficits in myelin debris clearance and OPC
differentiation. However, these findings were neither replicated
in GF mice, nor reversed by probiotic administration. Bringing
together these findings from different models, the microbiota
appears to shape the inflammatory response during CNS remyeli-
nation, but the effect of this on regenerative responses by OPCs
is limited.
We can postulate what the reasons may be for this disparity,
in which modulating the microbiota alters CNS inflammatory
responses without simultaneous changes in the efficiency of re-
myelination itself. It could be that the inflammatory changes that
our interventions provoked via the microbiota were simply not
sufficient to alter remyelination. This may be either a quantitative
limit (i.e. the changes in CNS inflammation caused by microbiota
modulation were too subtle), or a more qualitative limit (i.e. the
specific functions of microglia/macrophages that were affected
had minimal effect on remyelination). Indeed, as new molecular
techniques reveal further insights into microglial/macrophage
heterogeneity, the specific roles of these different phenotypes
during remyelination remain to be fully elucidated (25, 26). Simi-
larly, it cannot be excluded that other microbiota-based interven-
tions might be more fruitful in producing changes in the efficiency
of remyelination. However, we believe that our negative result
showing a lack of impact on remyelination using GF mice is
evidence against such a powerful influence.
In vitro, ABX did not directly influence microglial phagocyto-
sis or OPC differentiation, though other indirect effects of ABX
are difficult to exclude. Indeed, the differing balance of home-
ostatic and damage-associated microglia/macrophages between
GF and ABX-treated mice imply that our ABX treatment did
not simply imitate GF conditions. This may be due to other “off-
target” effects (undetected in our cell culture studies), or perhaps
an incomplete depletion of the microbiota, in turn allowing other











































































































































duced bacterial DNA by approximately 100-fold, other studies
have achieved a more extensive depletion (4). Regardless, the
lack of an effect on the proportion of myelinated axons at 14dpl
is evidence that remyelination itself is resilient to the changes in
inflammation that we provoked using antibiotics.
Interactions between microbiota and regeneration have been
observed in other tissues where contact is more direct. Skin
wounds heal faster in GF mice, associated with reduced neu-
trophil accumulation (49), whilst microbiota-derived lipopolysac-
charide (LPS) was found to dictate regenerative responses in
the intestinal crypt (50). Similarly, the regenerative capacity of
planaria was diminished by pathogenic shifts in their microbiota
(51). However, it seems likely that such interactions become
less relevant at anatomically distant sites – for example, the
evidence linking liver regeneration to the microbiota is more
contentious (52, 53). Outside a regenerative context, changes in
developmental or adaptive myelination in the CNS have previ-
ously been linked to the microbiota. GF mice are hypermyeli-
nated specifically in the prefrontal cortex (PFC) (54), whilst a
PFC hypomyelination phenotype could be transferred between
different strains of mice by FMT (55). Whilst a role for the
microbiota in myelin homeostasis is exciting, the findings of both
studies were region-specific and occur in a very different context
to remyelination, which is accompanied by tissue damage and a
robust inflammatory response.
Though neither our GF nor probiotic study demonstrated
a difference in remyelination, in both cases there was a pro-
tective effect of the intervention on demyelination, as seen by
increased numbers of oligodendrocytes at timepoints too early for
substantial OPC differentiation to have occurred. This could be
explained by the role of the immune system in mediating demyeli-
nation as well as remyelination in the lysolecithin and cuprizone
models (47, 48, 56, 57). Consistent with this idea, we observed
that both of these manipulations of the microbiota were asso-
ciated with reduced numbers of P2ry12loClec7a+ degeneration-
associated microglia/macrophages within the lesion. Similarly,
GF mice were resistant to immune-mediated CNS pathology in
a model of Parkinson’s disease (46), whilst changes in the im-
mune response with VSL#3 treatment were associated with white
matter preservation in a spinal cord contusion model (44). As the
immune system plays a prominent role in demyelination in MS,
the majority of previous work on the gut-brain axis has focused
on interventions that can limit inflammation and demyelination.
For example, in the immune-driven experimental autoimmune
encephalomyelitis (EAE) model, GF or antibiotics-treated mice
are resistant to demyelination (19, 58, 59).
In conclusion, we have highlighted the microbiota as a con-
tributing factor to the inflammatory response during CNS re-
myelination. However, the regenerative responses of OPCs were
largely independent of our interventions. The exception to this
was following broad-spectrum oral antibiotic treatment, during
which antibiotics do not inhibit OPCs directly, but may have other
off-target systemic effects. These findings identify high, combined
doses of oral antibiotics as a negative influence on OPC responses
during remyelination and further our understanding of the inter-
action between the microbiota and mammalian regeneration.
Materials and methods
For full details, see SI Appendix, Supplementary Materials and Methods.
Animal work. All animal work complied with the requirements and
regulations of the United Kingdom Home Office (Project Licences: 70/7715
and 2789) or the European Guidelines for animal welfare with approval from
the “Landesamt für Gesundheit und Soziales” (LAGeSo, Berlin registration
number: G0184/12).
Focal lysolecithin lesions in antibiotics-treated mice.A cocktail of antibi-
otics was administered via the drinking water to 4-month old female C57BL/6
mice for 8 weeks. The antibiotics used were: ampicillin/sulbactam (1.5g/L),
ciprofloxacin (200mg/L), vancomycin (500mg/L), metronidazole (1g/L) and
imipenem (250mg/L) – a regime previously employed to cause depletion of
microbes in the gut (4, 60). The faecal transplant group were then orally
gavaged with faecal material from control mice, once per day for 5 days,
whilst the antibiotics group continued to receive the antibiotics for the
duration of the experiment. The control group were housed in specific
pathogen free (SPF) conditions throughout. At age 7 months, demyelination
was initiated by stereotactic injection of 1μl lysolecithin (L4129, Sigma-
Aldrich, UK) into the thoracic spinal cord ventral white matter.
Cuprizone administration to germ-free mice. Male C57BL/6 mice were
bred from a GF nucleus colony at the University of East Anglia and main-
tained in a flexible-film isolator, supplied with sterilised air, food, water and
bedding. The GF group were maintained in these conditions throughout the
experiment and compared to aged-matched SPF controls. The ex-GF mice
were littermates of the GF group and remained in GF conditions until after
weaning (4 weeks old), at which point they acquired a microbiome by co-
housing with the SPF mice. Demyelination was initiated by administration of
a 0.2% cuprizone diet (TD.140803, Envigo, Huntingdon, UK), which received
50kGy γ-irradiation for sterilisation. All groups received the cuprizone diet
for 5 weeks beginning at age 2 months in place of their regular diet and
were then returned to regular diet for 3 weeks afterwards.
Focal lysolecithin lesions in probiotic-treated mice. 13-month old female
C57BL/6 mice were administered a daily dose of 1.35x109 colony forming
units of VSL#3 (a gift from Janine DeBeer, Ferring Pharmaceuticals, London,
UK), suspended in 100μl autoclaved water by oral gavage for 28 days. These
were compared to age-matched control mice, which were instead gavaged
daily with 100μl water. All groups received a focal injection of lysolecithin as
described in the antibiotics study.
Histological analysis. Standard techniques for immunohistochemistry
and preparation of resin sections were applied, as described previously (61).
For a full list of antibodies, please see SI appendix, Supplementary Materials
and Methods.
Cell culture. Microglia were isolated from 3-month old adult C57BL/6
mice using a Magnetic-Activated Cell Sorting (MACS) protocol (Fig. 3A),
similar to that described previously (62). After 48 hours, media was changed
tomacrophage serum-freemedium (Thermo Fisher Scientific, San Diego, CA),
containing the antibiotic treatments (Fig. S2A). Following a further 48 hours,
10μg/ml myelin debris was added to each well for 4 hours.
OPCs were isolated from P6-8 C57BL/6 mouse pups using a MACS
protocol (Fig. 3D), similar to that described previously (62). Cultures received
growth factors for the first 4 days (PDGFα and FGF2), after which antibiotic
treatments (Fig. S2A) were introduced for a further six days (replaced after
3 days) in the absence of growth factors to allow differentiation. 10μM 5-
ethynyl-2’-deoxyuridine (EdU) was applied for 3 hours prior to fixation.
Standard immunocytochemistry techniques were applied, as described
previously (62). For a full list of antibodies, please see SI appendix, Supple-
mentary Materials and Methods.
Image analysis. Cell counts were semi-automated, using a combination
of Fiji, CellProfiler and CellProfiler Analyst software (63). The region of
interest (ROI i.e. the lesion area) was manually defined by a blinded observer
using a composite image, based on Hoechst+ hypercellularity and non-
specific background staining. To quantify the area of a lesion occupied
by myelin debris, a threshold determined by background (median) dMBP
staining was applied to images in CellProfiler.
To quantify remyelination from toluidine blue-stained resin sections in
the probiotic study, slides of the 10 lesions (5 per group) were independently
ranked by two experienced, blinded investigators (GG and CZ) according to
the extent of remyelination. Ranks were based upon the proportion of each
lesion with thin myelin sheaths characteristic of remyelination, compared to
areas with persistently demyelinated axons. The assigned numerical order
(1-10) was used for subsequent non-parametric statistical tests. To quantify
remyelination from electron microscopy images, the internal and external
diameter of myelin sheaths were traced using a freehand selection tool in
Fiji. The g-ratio was calculated as the ratio between the diameters of two
circles with areas equal to the internal and external selections respectively.
Statistical analysis. All statistical analysis was carried out using a Jupyter
Notebook with Python 2. In vivo experiments contained the following num-
bers of biological replicates per group: antibiotics lysolecithin study: n=4-6
mice, germ-free cuprizone study: n=4-5 mice, probiotic lysolecithin study:
n=3-5 mice. These group sizes were chosen based on previous work and
were thought to be sufficiently powered to detect meaningful differences
in the OPC / inflammatory response to demyelination. For in vivo cell counts,
generally 3-4 technical replicate sections were counted and averaged per
biological replicate. For in vitro cell assays, 3-5 technical replicate wells were
averaged for each of 4-5 biological replicate studies.
Data was tested for normality of residuals (Kolmogorov-Smirnov test)
and homogeneity of variance (Levene’s test). Data sets passing both of these
criteria were compared by either unpaired Student’s t-test (if 2 groups),
or one-way ANOVA with Tukey HSD post hoc tests (if >2 groups). Non-
parametric data was compared by Mann-Whitney U test (2 groups) or
Kruskal-Wallis test with Dunn’s post hoc test (>2 groups). For in vitro assays,
treated conditions were compared to control conditions using a paired-
samples t-test with the Holm-Bonferroni correction formultiple comparisons.
For all statistical tests, differences were considered significant if p<0.05, and
the respective test is described in each figure legend.
In all bar plots, the height of the bar represents the group mean, with











































































































































are overlaid with strip plots, in which a grey point represents the value for
each individual animal.
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